ArticleEuropean heart journal. Digital health2026
Three-year risk prediction of aortic stenosis using routine medical records: derivation and validation in 919 954 individuals from two cohorts.
Article in European heart journal. Digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: All-cause mortality ranges between 33% and 42% for individuals with untreated moderate to severe aortic stenosis (AS). Transcatheter aortic valve replacement makes this a treatable condition, if identified early. Machine learning-based tools show great promise to predict cardiovascular outcomes. Methods and results: We developed and validated a machine learning model for 3-year prediction of AS risk (ASrisk) using serum biomarkers and vital sign measurements. We then evaluated the tool's capacity to identify diagnoses of AS sequelae, echocardiographic outcomes in individuals not diagnosed with AS, as well as enrichment and 3-year aortic valve area reduction in individuals with high ASrisk. Among 919 954 participants, 429 996 were from the Mount Sinai Data Warehouse (MSDW) [2179 (0.5%) AS cases] and 489 958 were from the UK Biobank [5066 (1%) AS cases]. Odds ratio (OR) of AS sequelae increased quantitatively with ascending deciles of ASrisk [OR 1.63 (95% CI 1.60-1.67) in MSDW]. Increasing ASrisk by 1 SD resulted in higher odds of echocardiographic findings in undiagnosed individuals [OR 1.88 (95% CI 1.71-2.06) for Doppler velocity index, OR 2.50 (95% CI 2.36-2.64) for aortic valve area, and OR 2.61 (95% CI 1.89-2.71) for mean gradient]. Three years after risk assessment, individuals with ASrisk > 0.95 show an 11-fold enrichment for AS diagnosis in both cohorts and an average reduction in aortic valve area of 0.42 cm Conclusion: ASrisk can predict risk of AS 3 years ahead of diagnosis in the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.